RU2012107812A - Препараты мутеинов липокалинов с контролируемым высвобождением - Google Patents
Препараты мутеинов липокалинов с контролируемым высвобождением Download PDFInfo
- Publication number
- RU2012107812A RU2012107812A RU2012107812/15A RU2012107812A RU2012107812A RU 2012107812 A RU2012107812 A RU 2012107812A RU 2012107812/15 A RU2012107812/15 A RU 2012107812/15A RU 2012107812 A RU2012107812 A RU 2012107812A RU 2012107812 A RU2012107812 A RU 2012107812A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- composition according
- lipocalin
- lipocalin mutein
- group
- Prior art date
Links
- 102000019298 Lipocalin Human genes 0.000 title claims abstract 38
- 108050006654 Lipocalin Proteins 0.000 title claims abstract 38
- 238000013270 controlled release Methods 0.000 title claims abstract 8
- 238000002360 preparation method Methods 0.000 title claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 46
- 229920001577 copolymer Polymers 0.000 claims abstract 18
- 229920000747 poly(lactic acid) Polymers 0.000 claims abstract 16
- 229920000954 Polyglycolide Polymers 0.000 claims abstract 14
- 229920002988 biodegradable polymer Polymers 0.000 claims abstract 12
- 239000004621 biodegradable polymer Substances 0.000 claims abstract 12
- 239000000203 mixture Substances 0.000 claims abstract 10
- 229920000642 polymer Polymers 0.000 claims abstract 9
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract 8
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract 8
- 102000004169 proteins and genes Human genes 0.000 claims abstract 8
- 108090000623 proteins and genes Proteins 0.000 claims abstract 8
- -1 polyacetyls Polymers 0.000 claims abstract 7
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims abstract 6
- 239000002502 liposome Substances 0.000 claims abstract 6
- 229920002732 Polyanhydride Polymers 0.000 claims abstract 5
- 229920001273 Polyhydroxy acid Polymers 0.000 claims abstract 5
- 229920001710 Polyorthoester Polymers 0.000 claims abstract 5
- 150000004676 glycans Chemical class 0.000 claims abstract 4
- 229920001282 polysaccharide Polymers 0.000 claims abstract 4
- 239000005017 polysaccharide Substances 0.000 claims abstract 4
- 239000004952 Polyamide Substances 0.000 claims abstract 3
- 150000002632 lipids Chemical class 0.000 claims abstract 3
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 claims abstract 3
- 229920002647 polyamide Polymers 0.000 claims abstract 3
- 229920001610 polycaprolactone Polymers 0.000 claims abstract 3
- 229920000515 polycarbonate Polymers 0.000 claims abstract 3
- 239000004417 polycarbonate Substances 0.000 claims abstract 3
- 229920002721 polycyanoacrylate Polymers 0.000 claims abstract 3
- 239000000622 polydioxanone Substances 0.000 claims abstract 3
- 229920002635 polyurethane Polymers 0.000 claims abstract 3
- 239000004814 polyurethane Substances 0.000 claims abstract 3
- 229920001308 poly(aminoacid) Polymers 0.000 claims abstract 2
- 229920000570 polyether Polymers 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims 26
- 102000009027 Albumins Human genes 0.000 claims 12
- 108010088751 Albumins Proteins 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 101000946124 Homo sapiens Lipocalin-1 Proteins 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 229920001477 hydrophilic polymer Polymers 0.000 claims 6
- 239000008346 aqueous phase Substances 0.000 claims 5
- 238000002347 injection Methods 0.000 claims 5
- 239000007924 injection Substances 0.000 claims 5
- 102100034724 Lipocalin-1 Human genes 0.000 claims 4
- 239000012074 organic phase Substances 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 3
- 102000014914 Carrier Proteins Human genes 0.000 claims 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- 102000013382 Gelatinases Human genes 0.000 claims 3
- 108010026132 Gelatinases Proteins 0.000 claims 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 3
- 102100035405 Neutrophil gelatinase-associated lipocalin Human genes 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 239000003809 bile pigment Substances 0.000 claims 3
- 108091008324 binding proteins Proteins 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000003995 emulsifying agent Substances 0.000 claims 3
- 150000002500 ions Chemical class 0.000 claims 3
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical group CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims 3
- 239000011859 microparticle Substances 0.000 claims 3
- 239000002105 nanoparticle Substances 0.000 claims 3
- 210000000440 neutrophil Anatomy 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 101000757556 Homo sapiens Apolipoprotein D Proteins 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 108010057281 Lipocalin 1 Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims 2
- 241000255969 Pieris brassicae Species 0.000 claims 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 2
- 108090000848 Ubiquitin Proteins 0.000 claims 2
- 102000044159 Ubiquitin Human genes 0.000 claims 2
- 239000013566 allergen Substances 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 239000006184 cosolvent Substances 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 238000004945 emulsification Methods 0.000 claims 2
- 235000019441 ethanol Nutrition 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 150000004665 fatty acids Chemical class 0.000 claims 2
- 210000004907 gland Anatomy 0.000 claims 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 2
- 102000056778 human APOD Human genes 0.000 claims 2
- 230000005847 immunogenicity Effects 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical group CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims 2
- 229920001281 polyalkylene Polymers 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 239000002243 precursor Substances 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 102000029752 retinol binding Human genes 0.000 claims 2
- 108091000053 retinol binding Proteins 0.000 claims 2
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 claims 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical group O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims 2
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 claims 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 claims 1
- UOBYKYZJUGYBDK-UHFFFAOYSA-M 2-naphthoate Chemical compound C1=CC=CC2=CC(C(=O)[O-])=CC=C21 UOBYKYZJUGYBDK-UHFFFAOYSA-M 0.000 claims 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 claims 1
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 claims 1
- 102000009333 Apolipoprotein D Human genes 0.000 claims 1
- 108010025614 Apolipoproteins D Proteins 0.000 claims 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 241000282472 Canis lupus familiaris Species 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 102100022103 Histone-lysine N-methyltransferase 2A Human genes 0.000 claims 1
- 108050002855 Histone-lysine N-methyltransferase 2A Proteins 0.000 claims 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 108010051335 Lipocalin-2 Proteins 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical group O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical group ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 235000021314 Palmitic acid Nutrition 0.000 claims 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 claims 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims 1
- 239000004743 Polypropylene Substances 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 108700011201 Streptococcus IgG Fc-binding Proteins 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 229940050528 albumin Drugs 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 150000001299 aldehydes Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 claims 1
- 239000012964 benzotriazole Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 150000007942 carboxylates Chemical class 0.000 claims 1
- 238000000354 decomposition reaction Methods 0.000 claims 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 claims 1
- 229940043264 dodecyl sulfate Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 239000000787 lecithin Substances 0.000 claims 1
- 229940067606 lecithin Drugs 0.000 claims 1
- 235000010445 lecithin Nutrition 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 1
- KHARCSTZAGNHOT-UHFFFAOYSA-L naphthalene-2,3-dicarboxylate Chemical compound C1=CC=C2C=C(C([O-])=O)C(C(=O)[O-])=CC2=C1 KHARCSTZAGNHOT-UHFFFAOYSA-L 0.000 claims 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 claims 1
- 229920000620 organic polymer Polymers 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 108091009565 pigment binding proteins Proteins 0.000 claims 1
- 239000002745 poly(ortho ester) Substances 0.000 claims 1
- 229920001515 polyalkylene glycol Polymers 0.000 claims 1
- 229920000728 polyester Polymers 0.000 claims 1
- 229920001155 polypropylene Polymers 0.000 claims 1
- 229920001451 polypropylene glycol Polymers 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 229940068965 polysorbates Drugs 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 229940068984 polyvinyl alcohol Drugs 0.000 claims 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 claims 1
- 108020001580 protein domains Proteins 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 208000004644 retinal vein occlusion Diseases 0.000 claims 1
- 229960000953 salsalate Drugs 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 229960002317 succinimide Drugs 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
- WILNLXGNKANPKN-UHFFFAOYSA-N trifluoromethyl 4-methylbenzoate Chemical compound CC1=CC=C(C(=O)OC(F)(F)F)C=C1 WILNLXGNKANPKN-UHFFFAOYSA-N 0.000 claims 1
- 210000004127 vitreous body Anatomy 0.000 claims 1
- 239000002966 varnish Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23136509P | 2009-08-05 | 2009-08-05 | |
| US61/231,365 | 2009-08-05 | ||
| PCT/EP2010/061436 WO2011015634A2 (en) | 2009-08-05 | 2010-08-05 | Controlled release formulations of lipocalin muteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012107812A true RU2012107812A (ru) | 2013-09-10 |
Family
ID=43531164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012107812/15A RU2012107812A (ru) | 2009-08-05 | 2010-08-05 | Препараты мутеинов липокалинов с контролируемым высвобождением |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20120201873A1 (enExample) |
| EP (2) | EP2461800A2 (enExample) |
| JP (2) | JP2013501033A (enExample) |
| KR (1) | KR20120099371A (enExample) |
| CN (2) | CN102612362A (enExample) |
| AU (2) | AU2010280688A1 (enExample) |
| BR (1) | BR112012002709A2 (enExample) |
| CA (1) | CA2770149A1 (enExample) |
| IN (1) | IN2012DN00407A (enExample) |
| RU (1) | RU2012107812A (enExample) |
| WO (1) | WO2011015634A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2791278C (en) | 2010-02-25 | 2015-11-24 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
| WO2012109363A2 (en) | 2011-02-08 | 2012-08-16 | The Johns Hopkins University | Mucus penetrating gene carriers |
| WO2012118323A2 (ko) * | 2011-02-28 | 2012-09-07 | 고려대학교 산학협력단 | 알부민과 레티놀 결합 단백질의 융합 단백질 |
| US10064915B2 (en) | 2011-02-28 | 2018-09-04 | Korea University Research And Business Foundation | Fusion protein comprising albumin and retinol-binding protein |
| US9701732B2 (en) | 2011-02-28 | 2017-07-11 | Korea University Research And Business Foundation | Fusion protein comprising albumin and retinol-binding protein |
| BR112013027222B1 (pt) * | 2011-06-14 | 2022-07-12 | Ipsen Pharma S.A.S. | Composição de liberação sustentada que contém peptídeos como ingrediente ativo |
| WO2013068590A1 (en) * | 2011-11-11 | 2013-05-16 | Pieris Ag | Lipocalin muteins as vegf antagonists for use in treating diseases caused or promoted by increased vascularization |
| EP2802341B1 (en) * | 2012-01-09 | 2019-03-06 | Pieris Pharmaceuticals GmbH | Methods for preventing, treating or diagnosing disorders |
| JP6184982B2 (ja) | 2012-02-02 | 2017-08-23 | エスバテック − ア ノバルティス カンパニー エルエルシー | 点眼用抗体含有徐放性製剤 |
| EP2825207B1 (en) | 2012-03-16 | 2020-08-19 | The Johns Hopkins University | Non-linear multiblock copolymer-drug conjugates for the delivery of active agents |
| AU2013232297B2 (en) | 2012-03-16 | 2016-01-14 | The Johns Hopkins University | Controlled release formulations for the delivery of HIF-1 inhibitors |
| US9533068B2 (en) | 2012-05-04 | 2017-01-03 | The Johns Hopkins University | Drug loaded microfiber sutures for ophthalmic application |
| WO2014124006A1 (en) | 2013-02-05 | 2014-08-14 | The Johns Hopkins University | Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof |
| CN103394094B (zh) * | 2013-07-16 | 2015-05-13 | 天津大学 | 基于牛血清白蛋白-聚己内酯的高分子脂质体及其制备方法 |
| CN103360609B (zh) * | 2013-07-16 | 2015-08-19 | 天津大学 | 一种双亲性的蛋白质-高分子键合体及其制备方法 |
| US10927154B2 (en) | 2014-01-13 | 2021-02-23 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| US20160151511A1 (en) | 2014-12-02 | 2016-06-02 | Antriabio, Inc. | Proteins and protein conjugates with increased hydrophobicity |
| CA2974715C (en) | 2015-01-27 | 2020-05-05 | The Johns Hopkins University | Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces |
| AU2016258977C1 (en) | 2015-05-04 | 2022-07-14 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
| BR112018016774A2 (pt) * | 2016-02-16 | 2018-12-26 | Strongbridge Ireland Limited | veldoreotídeo com fraca solubilidade em condições fisiológicas para o uso no tratamento da acromegalia, câncer em acromegalia, tumores que expressam sst-r5, diabetes tipo 2, hiperglicemia e tumores relacionados a hormônio |
| US12496279B2 (en) | 2019-04-11 | 2025-12-16 | The Johns Hopkins University | Nanoparticles for drug delivery to brain |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5349052A (en) | 1988-10-20 | 1994-09-20 | Royal Free Hospital School Of Medicine | Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor |
| IE912365A1 (en) | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US5417982A (en) * | 1994-02-17 | 1995-05-23 | Modi; Pankaj | Controlled release of drugs or hormones in biodegradable polymer microspheres |
| US5650234A (en) | 1994-09-09 | 1997-07-22 | Surface Engineering Technologies, Division Of Innerdyne, Inc. | Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces |
| US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| WO1997004747A1 (en) | 1995-07-27 | 1997-02-13 | Dunn James M | Drug delivery systems for macromolecular drugs |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| CN1170543C (zh) | 1998-06-08 | 2004-10-13 | 弗·哈夫曼-拉罗切有限公司 | PEG-IFN-α和三唑核苷在治疗慢性丙型肝炎中的用途 |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| BR9917517A (pt) | 1999-10-08 | 2002-07-30 | Shearwater Corp | Derivados poliméricos heterobifuncionais e processo para a preparação dos mesmos |
| AU2000202A (en) * | 2000-10-31 | 2002-05-15 | Pr Pharmaceuticals Inc | Methods and compositions for enhanced delivery of bioactive molecules |
| EP1377306A1 (en) | 2001-03-09 | 2004-01-07 | Dyax Corp. | Serum albumin binding moieties |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| EP1430136A1 (en) | 2001-09-27 | 2004-06-23 | Pieris ProteoLab AG | Muteins of apolipoprotein d |
| BRPI0409322B8 (pt) | 2003-04-11 | 2021-05-25 | Antriabio Inc | método para preparar um conjugado de insulina-polímero |
| WO2005009356A2 (en) * | 2003-07-15 | 2005-02-03 | Pr Pharmaceuticals, Inc. | Method for the preparation of controlled release formulations |
| AU2004259209A1 (en) * | 2003-07-23 | 2005-02-03 | Pr Pharmaceuticals, Inc. | Controlled release compositions |
| WO2005019255A1 (en) * | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| US7691970B2 (en) | 2003-08-25 | 2010-04-06 | Pieris Ag | Muteins of a bilin-binding protein with affinity for a given target |
| EP2899277A1 (en) | 2004-11-26 | 2015-07-29 | Pieris AG | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| WO2007038619A2 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
| US8598317B2 (en) * | 2006-03-20 | 2013-12-03 | Technische Universitaet Muenchen | Muteins of tear lipocalin with affinity for the T-cell coreceptor CD4 |
| SG173332A1 (en) * | 2006-08-01 | 2011-08-29 | Pieris Ag | Muteins of tear lipocalin and methods for obtaining the same |
| US8178483B2 (en) * | 2007-03-30 | 2012-05-15 | Colgate-Palmolive Company | Polymeric encapsulates having a quaternary ammonium salt and methods for producing the same |
| EP2142293A2 (de) * | 2007-04-26 | 2010-01-13 | Basf Se | Enzymatisches verfahren zur herstellung von mikrokapseln |
| ES2443537T3 (es) * | 2007-07-26 | 2014-02-19 | Aqtis Ip Bv | Micropartículas que comprenden PCL y usos de las mismas |
| EP2249809A1 (en) * | 2008-01-15 | 2010-11-17 | Abbott GmbH & Co. KG | Powdered protein compositions and methods of making same |
| CN106986926A (zh) * | 2008-01-30 | 2017-07-28 | 皮里斯股份公司 | 具有对人c‑met受体酪氨酸激酶的亲和性的泪脂质运载蛋白的突变蛋白及其获得方法 |
| US20090274623A1 (en) * | 2008-01-30 | 2009-11-05 | General Electric Company | In vivo imaging agents for met receptor tyrosine kinase |
-
2010
- 2010-08-05 AU AU2010280688A patent/AU2010280688A1/en not_active Abandoned
- 2010-08-05 US US13/388,788 patent/US20120201873A1/en not_active Abandoned
- 2010-08-05 EP EP10747840A patent/EP2461800A2/en not_active Withdrawn
- 2010-08-05 EP EP12177932.6A patent/EP2550958B1/en not_active Not-in-force
- 2010-08-05 RU RU2012107812/15A patent/RU2012107812A/ru not_active Application Discontinuation
- 2010-08-05 CA CA2770149A patent/CA2770149A1/en not_active Abandoned
- 2010-08-05 CN CN2010800348503A patent/CN102612362A/zh active Pending
- 2010-08-05 WO PCT/EP2010/061436 patent/WO2011015634A2/en not_active Ceased
- 2010-08-05 IN IN407DEN2012 patent/IN2012DN00407A/en unknown
- 2010-08-05 BR BR112012002709-3A patent/BR112012002709A2/pt not_active IP Right Cessation
- 2010-08-05 CN CN201610084958.2A patent/CN106139123A/zh active Pending
- 2010-08-05 KR KR1020127005597A patent/KR20120099371A/ko not_active Ceased
- 2010-08-05 JP JP2012523344A patent/JP2013501033A/ja active Pending
-
2012
- 2012-08-08 JP JP2012176112A patent/JP5774557B2/ja not_active Expired - Fee Related
-
2016
- 2016-07-07 AU AU2016204715A patent/AU2016204715A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016204715A1 (en) | 2016-07-28 |
| JP2013501033A (ja) | 2013-01-10 |
| WO2011015634A2 (en) | 2011-02-10 |
| KR20120099371A (ko) | 2012-09-10 |
| BR112012002709A2 (pt) | 2019-04-30 |
| EP2550958A1 (en) | 2013-01-30 |
| EP2461800A2 (en) | 2012-06-13 |
| EP2550958B1 (en) | 2018-10-10 |
| AU2010280688A1 (en) | 2012-02-23 |
| CN106139123A (zh) | 2016-11-23 |
| IN2012DN00407A (enExample) | 2015-08-21 |
| JP2012255007A (ja) | 2012-12-27 |
| JP5774557B2 (ja) | 2015-09-09 |
| US20120201873A1 (en) | 2012-08-09 |
| CA2770149A1 (en) | 2011-02-10 |
| WO2011015634A3 (en) | 2011-04-14 |
| CN102612362A (zh) | 2012-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013501033A5 (enExample) | ||
| Asfour | Advanced trends in protein and peptide drug delivery: a special emphasis on aquasomes and microneedles techniques | |
| Abdellatif et al. | Approved and marketed nanoparticles for disease targeting and applications in COVID-19 | |
| Nie et al. | Sustained release systems for delivery of therapeutic peptide/protein | |
| Tan et al. | Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery | |
| JP5774557B2 (ja) | リポカリン突然変異タンパク質の制御放出製剤 | |
| Hu et al. | Lactoferrin-conjugated PEG–PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations | |
| Merkle | Drug delivery’s quest for polymers: Where are the frontiers? | |
| JP5964373B2 (ja) | 糖尿病および他の慢性疾患の治療に有用な組成物 | |
| JP5912082B2 (ja) | Ｒ−ｇ−システイン酸ペプチドを含む医薬組成物 | |
| Pai et al. | Poly (ethylene glycol)-modified proteins: implications for poly (lactide-co-glycolide)-based microsphere delivery | |
| US20190225670A1 (en) | Compounds and methods for activating tie2 signaling | |
| JP2017105830A (ja) | Ｒ−ｇ−システイン酸ペプチドを含む医薬組成物 | |
| JP2007524645A (ja) | 制御放出処方物の調製のための方法 | |
| Sinha et al. | Biodegradable microspheres for parenteral delivery | |
| CN101610783B (zh) | 脊髓损伤治疗剂 | |
| CA2805728A1 (en) | Microparticles comprising a small heat-shock protein | |
| Srinivas et al. | Protein and peptide drug delivery-a brief review | |
| US20040142887A1 (en) | Antigen-polymer compositions | |
| Zhang et al. | Highly Efficient Intrastromal Dual-Drug Delivery by a Dissolving Bilayer Microneedle for Synergistic Therapy against Corneal Neovascularization | |
| US11369575B2 (en) | PPARα agonist compositions and methods of use | |
| CN101389356B (zh) | 药物输送物质 | |
| US11674959B2 (en) | Methods for identifying and preparing pharmaceutical agents for activating Tie1 and/or Tie2 receptors | |
| Jani et al. | Pharmaceutical approaches related to systemic delivery of protein and peptide drugs: an overview | |
| CN119390758B (zh) | 一种靶向dec-205口服疫苗及其构建方法与应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160906 |